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Background: Cardiac resynchronisation therapy (CRT) induces progressive reverse left ventricular (LV) remodelling and slows disease progression 
in NYHA III-IV patients with a more pronounced effect on remodelling in non-ischemic patients. We hypothesized that the effects of CRT in less severe 
heart failure (HF) patients might also be related to HF etiology.
Method: 262 patients in Europe with NYHA class I or II HF were randomly assigned to an active CRT group (CRT ON; 180 patients) or a control 
group (CRT OFF; 82 patients) for 24 months in the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. 
The study’s primary endpoint, the HF clinical composite response, and the prospectively powered secondary endpoint, LV end-systolic volume index 
(LVESVi), along with mortality and first HF hospitalization or death were evaluated in relation to HF etiology.
Results: The 24-month effects of CRT on the different endpoints are shown in the table.
Conclusion: REVERSE demonstrates that CRT improves clinical outcomes in both ischemic and non-ischemic patients with asymptomatic and 
mildly symptomatic HF. The effect on heart size is more pronounced in non-ischemic patients. 
Non-ischemic (n=148) Ischemic (n=114)
CRT OFF (n=48) CRT ON (n=100) CRT OFF (n=34) CRT ON (n=80)
Clinical Composite Response
Distribution
Improved 33% 58% 24% 49%
Unchanged 35% 23% 38% 33%
Worsened 31% 19% 38% 19%
P-value 0.02 0.02
Change in LVESVi (ml/m2)
Mean ± S.D. -2.0 ± 32.4 -36.9 ± 32.4 -3.4 ± 14.9 -16.3 ± 27.3
P-value <0.0001 0.007
Mortality
% at 24 months 8% 1% 9% 6%
P-value 0.02 0.69
First HF hospitalization or death
% at 24 months 23% 8% 24% 11%
P-value 0.01 0.09
